Hello, Fool! | Login | Signup | My Fool
Aug 30, 2008 7:45 AM ET | Site Changes | Help
A biotechnology company focused on the development and commercialization of novel biological therapies for patients with cancer.
View Ticker Page (CEGE)
Results 21 - 30 of 59 : 12345Next »
Recs
Shadow14US (28.47) Submitted: 3/13/08 9:29 PM : Start Price: $2.15 CEGE Score: -51.42
Showing nice growth since purchase.
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
KatWoman50 (96.01) Submitted: 3/28/08 12:11 PM : Start Price: $2.48 CEGE Score: -57.54
In a race with Dendreon for prostate cancer vaccination. What will be approved first, Provenge or GVAX?
Imbythelake (67.41) Submitted: 2/18/08 9:47 PM : Start Price: $2.49 CEGE Score: -54.86
The new GVAX cancer drug has showed encouraging progress. S&P stock report gives it 4 out of 5 stars for buy. An acquisition by Glaxo is rumored down the road.Signs point to buy.
Dougmink (28.23) Submitted: 4/15/07 9:49 AM : Start Price: $5.30 CEGE Score: -69.82
CEGE is working on a cancer vaccine. Cancer vaccines have never been approved by the FDA but it looks like the process will be approved for the first time with the Dendreon vaccine. This should make it easier for CEGE to get its vaccine apporved si...
idkblablabla (< 20) Submitted: 4/09/07 6:56 PM : Start Price: $7.09 CEGE Score: -75.41
I expect much upside as CEGE continues to follow DNDN up. Even a break in DNDN may not stop CEGE from hitting $10 in the next few weeks. I expect $10 by May 14th, if not much sooner. Obviously this is high-risk and tight money management should be...
Report this Post Replies: 5 | Reply | Permalink
astough (< 20) Submitted: 9/19/06 3:59 AM : Start Price: $4.68 CEGE Score: -76.54
This stock will soar when clinical trials are complete and FDA approval is granted. It is largely insider owned.
riley20 (< 20) Submitted: 9/06/06 2:06 AM : Start Price: $5.23 CEGE Score: -79.66
superb intellectual property in cancer vacines. Two Ph III trials in prostrate cancer and multiple Ph II trials. Well funded and trading just over cash.
LionShare4jp (< 20) Submitted: 4/15/08 10:07 AM : Start Price: $3.09 CEGE Score: -64.89
A Cure for Cancer? It's unlikely, but any new treatments that would improve patient survivall would be a good start.Competes with DNDN Provenge, and Provenge did miss it's endpoints.
waewens (< 20) Submitted: 4/01/08 4:10 PM : Start Price: $3.09 CEGE Score: -62.11
The results of the 2 phase III trial will not be given out until 2009. This will be the real indicator of where this stock and company is going. There has to be some potential for this stock if Takeda is will to put up millions of dollars with a p...
jpokergman (< 20) Submitted: 4/01/08 3:28 AM : Start Price: $2.91 CEGE Score: -62.67
beat cancer may people live longer and better.....
Terms & Conditions
RSS Headlines
Fool UK